keyword
MENU ▼
Read by QxMD icon Read
search

ovarian cyts management

keyword
https://www.readbyqxmd.com/read/8462896/clinical-assessment-of-111in-cyt-103-immunoscintigraphy-in-ovarian-cancer
#1
MULTICENTER STUDY
E A Surwit, J M Childers, D N Krag, J G Katterhagen, H H Gallion, S Waggoner, W J Mann
The ability of 111In-CYT-103 immunoscintigraphy to aid in the diagnosis of patients with primary or recurrent/residual ovarian cancer was evaluated in a multicenter trial. The 111In-labeled immunoconjugate of the monoclonal antibody B72.3 was prepared using a site-specific conjugation method. A total of 103 patients received a 1 mg infusion of 111In-CYT-103 and subsequently underwent surgery or biopsy. The infusion of 111In-CYT-103 was well tolerated; only 1 patient experienced a modest elevation in blood pressure that was likely related to the infusion...
March 1993: Gynecologic Oncology
https://www.readbyqxmd.com/read/8441055/clinical-utility-of-immunoscintigraphy-in-managing-ovarian-cancer
#2
D N Krag
Ovarian cancer spreads to multiple areas of the peritoneal cavity early in the course of the disease. Multiple small foci of tumor are not identified readily with standard preoperative staging procedures. A review of an immunoscintigraphy study of more than 100 women preoperatively staged with 111In-labeled B72.3 (CYT-103) reveals that this technique has a low potential for serious side effects and it can identify miliary spread of ovarian cancer and extra-abdominal metastases. It has the potential to contribute favorably to patient management by detecting occult lesions, may define the extent of tumor as well or better than computerized tomography and may impact on surgical decision-making...
March 1993: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/8242578/immunoscintigraphy-in-patients-with-colorectal-ovarian-and-prostate-cancer-results-with-site-specific-immunoconjugates
#3
REVIEW
R T Maguire, V L Pascucci, A N Maroli, J V Gulfo
Application of monoclonal antibody (MoAb) technology to cancer management is discussed by reviewing the development and clinical evaluation of two MoAb-based immunoscintigraphic agents (111In-satumomab pendetide [OncoScint CR/OV-In] and 111In-CYT-356; Cytogen Corporation, Princeton, NJ). Both agents were prepared using a site-specific MoAb modification method that preserves the immunoreactivity of the radiolabeled immunoconjugate. 111In-satumomab pendetide is an 111In-labeled conjugate of the murine MoAb B72...
December 1, 1993: Cancer
https://www.readbyqxmd.com/read/1576343/impact-of-111in-cyt-103-on-the-surgical-management-of-patients-with-ovarian-cancer
#4
MULTICENTER STUDY
E A Surwit
No abstract text is available yet for this article.
1992: Targeted Diagnosis and Therapy
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"